Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
May 21, 2024 17:15 ET
|
Alvotech
Total revenues in Q1 2024 increased to $37 million compared to $16 million in the same period last year. Gross margin in Q1 2024 increased to $17 million, by $40 million compared to the same period...
Alvotech birtir uppgjör fyrir fyrsta ársfjórðung 2024 og kynnir nýjustu áfanga í rekstri félagsins
May 21, 2024 17:14 ET
|
Alvotech
Heildartekjur á fyrsta ársfjórðungi 2024 jukust í 37 milljónir dollara, úr 16 milljónum dollara á sama tímabili í fyrraFramlegð á fyrsta fjórðungi 2024 var 17 milljónir dala, sem er 40 milljóna...
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
May 21, 2024 17:14 ET
|
Alvotech
Total revenues in Q1 2024 increased to $37 million compared to $16 million in the same period last yearGross margin in Q1 2024 increased to $17 million, by $40 million compared to the same period last...
Alvotech gengur til samstarfs við Dr. Reddy‘s um markaðssetningu AVT03, fyrirhugaðrar hliðstæðu við Prolia og Xgeva, í Bandaríkjunum og Evrópu
May 21, 2024 08:01 ET
|
Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að fyrirtækið hefði gert samstarfssamning við Dr. Reddy’s Laboratories SA, dótturfyrirtæki Dr. Reddy’s Laboratories Ltd. (“Dr. Reddy’s”) um sölu- og...
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
May 21, 2024 08:01 ET
|
Alvotech
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)Alvotech will be responsible for development and...
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
May 21, 2024 08:00 ET
|
Alvotech
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK) Alvotech will be responsible for development and...
ECARX-Powered Lynk & Co. 07 EM-P Sedan Began Deliveries in China
May 21, 2024 07:00 ET
|
ECARX LIMITED
SHANGHAI, China, May 21, 2024 (GLOBE NEWSWIRE) -- ECARX Holdings Inc. (Nasdaq: ECX) (“ECARX” or the “Company”), a global mobility technology company, today congratulated Lynk & Co on the first...
HRBR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Harbor Diversified, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
May 21, 2024 04:00 ET
|
Bronstein, Gewirtz & Grossman, LLC
NEW YORK, May 21, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been...
Alvotech og Teva Pharmaceuticals hefja sölu á líftæknilyfjahliðstæðunni Simlandi í Bandaríkjunum
May 20, 2024 20:25 ET
|
Alvotech
Simlandi er fyrsta líftæknilyfjahliðstæðan í háum styrk með útskiptanleika við Humira á markaði í Bandaríkjunum Alvotech (NASDAQ: ALVO) og samstarfsaðili þess Teva Pharmaceuticals Ltd. tilkynntu í...
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
May 20, 2024 20:25 ET
|
Alvotech
SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira® REYKJAVIK, ICELAND & PARSIPPANY, NJ — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical...